# Bristol Myers Squibb and Erasca Arrange Evaluation of Cancer Drug Pair

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/60743
Published: 2026-11-18T18:31:22.000Z
Updated: 2026-11-18T18:31:22.000Z
Section: Business

> Erasca will supply ERAS-0015 for the evaluation, which focuses on pancreatic ductal adenocarcinoma.

Bristol Myers Squibb and Erasca have arranged to evaluate a drug combination of navlimetostat with ERAS-0015 for pancreatic ductal adenocarcinoma, the most prevalent pancreatic cancer type.

ERAS-0015 is a pan-RAS molecular glue, and Erasca will supply it for the evaluation. Navlimetostat is the other compound in the combination.


